AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05812287 — intervention group
Intervention type: OTHER
Intervention: Detection of biological samples based on multi-omics analysis
Description: In this study, we combined microbiological (16SrRNA) and metabolomic mass spectrometry to study the changes in microbial populations and metabolic profiles of various samples such as feces, serum, and saliva, and screen key differential markers.
Study NCT05103293 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: patient-derived tumor-like cell clusters drug sensitivity test
Description: Intervention Description：Neoadjuvant therapy regimen of patients in the PTC group is guided by PTC drug sensitivity results. After operation, adjuvant targeted therapy for pCR patients is based on original treatment, adjuvant targeted therapy for non-pCR patients is based on a secondary PTC drug sensitivity results.
Study NCT04916080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: mucolytic and anti-oxidant. Dose 10mg/Kg/ 12 hours orally
Study NCT03966807 — intervention group
Intervention type: BEHAVIORAL
Intervention: Digital-based support
Description: Digital support will consist of referral for the participant to visit https://smokefree.gov, a website which offers a menu of internet- and text-based support options.
Study NCT03966807 — intervention group
Intervention type: BEHAVIORAL
Intervention: Traditional-based support + Nicotine replacement therapy (NRT)
Description: Traditional support will consist of participant referral to the Indiana Tobacco Quitline (1-800-QUIT-NOW) which is a telephone hotline that connects participants to Indiana smoking cessation resources.
Study NCT05237661 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moon Balance
Description: Moon Balance is a blend of 6 food ingredients
Study NCT04951154 — intervention group
Intervention type: OTHER
Intervention: Bronchoscopic Biopsy
Description: Bronchoscopic biopsies will be used to evaluate biomarkers of tumor biology and immunology.
Study NCT04951154 — intervention group
Intervention type: OTHER
Intervention: Blood Sample
Description: Blood samples will be obtained to measure circulating biomarkers.
Study NCT05071196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facilitated Vegan Diet
Description: Vegan boxed meal kits
Study NCT05071196 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Omnivorous Diet
Description: Non-vegan boxed meal kits
Study NCT06056167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degludec insulin
Description: Enrolled patients will be initiated on regular insulin sliding scale (ISS) every 6 hours, administrated subcutaneously at 0600, 1200, 1800 and 2400 in patients who are nil per os and on intravenous fluid or parenteral nutrition or continuous tube feeding, according to King Faisal Specialist Hospital \& Research Center (KFSH\&RC) protocol.~Patients with two capillary point of care glucose levels of > 10 mmol/L (180 mg/dl) will be initiated on insulin degludec at dose of 0.2 units/ kg.~Dose adjustments will be carried out on daily basis based on blood glucose levels following a written protocol.
Study NCT03752918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: A single dose of 1.5mg/kg will be administered once orally.
Study NCT03752918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Niacin
Description: A single dose of 250mg will be administered once orally.
Study NCT05232994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20mg
Description: Combination 2 g of oral extended release metformin, Esomeprazole 20mg daily until delivery.
Study NCT05352568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Computer-Based Cognitive Training from BrainHQ (Posit Science)
Study NCT05532943 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord mesenchymal stem cells
Description: UMSC01 cells will be IV infusion followed by IT infusion with 12 months of follow up after treatment.
Study NCT05532943 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: Normal saline will be IV infusion followed by sham-IT infusion with 12 months of follow up after treatment.
Study NCT04778423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avatar Therapy
Description: In the first session (assessment), participants will create a computerised representation of the eating disorder voice (avatar) on a computer. They will be able to manipulate the facial and voice characteristics of the avatar and will be asked to provide examples of the critical eating disorder comments most often spoken by the avatar. In the following sessions (6-8 therapy sessions), participants will interact with the avatar displayed on the computer screen for 5-10 minutes.The main goal during the interaction with the avatar is for participants to stand up to the critical comments made by the avatar and build a sense of power, control and self-awareness in the context of the eating disorder voice. The sessions will be conducted remotely, using a personal laptop or computer. This will provide patients with the opportunity to practise answering back to the eating disorder voice during a meal, a time at which the eating disorder voice is loudest.
Study NCT04819607 — intervention group
Intervention type: OTHER
Intervention: model of care
Description: Multidisciplinary model of care for BMFS patients.
Study NCT04911296 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mock-RP
Description: Standard 000 capsule filled with potato starch, enteric-coated with colorant and lubricious coating.
Study NCT05354596 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: STRICT LUNG
Description: Stereotactic body radiation therapy: Centrally located tumors are treated on standard-linacs with daily CBCT image-guidance and plan adaptation.
Study NCT05354596 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: STAR LUNG
Description: Stereotactic body radiation therapy: Ultra-centrally tumors are treated on MR-linacs with daily MR-guided plan-adaptation.
Study NCT04383210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seribantumab
Description: Anti-HER3 monoclonal antibody
Study NCT06086717 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Taping
Description: One Y-shaped strap with 25% stretch was applied from the mid third of the thigh over the rectus femoris, then its ends directed toward the tibial tuberosity by enwrapping the patella from lateral and medial sides. In 45° knee flexion one eye strap from medial to lateral was applied through the collateral medial and lateral ligaments.~For the facilitation of VMO 1 eye strap with 25% stretch from medial aspect of thigh to quadriceps tendon. Lastly, 1 eye strap with 25% stretch from tibial tuberosity to lateral aspect of thigh for inhibition of Vastus lateralis
Study NCT06086717 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling
Description: Following a protocol according to patient and limb, the tensor fasciae latae, hip adductors, hamstrings, quadriceps, gastrocnemius, and popliteus muscles were properly examined in each subject. These muscles are frequently involved in muscle-related knee pain.~Patients with knee OA who had at least one active MTrP that produced pain were recruited. Patients received a total of 8 DN sessions (2 sessions per week for 4 weeks) at all MTrPs of the lower limbs using the fast-in and fast-out technique (the needle was moved up and down within the muscle).
Study NCT05154786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Mobilization and endurance training
Description: The early mobilization and endurance training will be conducted with grading exercise level. In the course of endurance training. After achieving patient's active participation in sitting on the bed, the goal will be to train for at least 20 min. If this is accomplished, exercise level and training period increased until a maximum of 7 on modified RPE. If these are well-tolerated and no contraindications as per medical prescription exist, the treatment will be further advanced to mobilizing participants to the bedside. After being able to sit for at least 10 min on the side of the bed, regardless of whether support is needed, participants will be moved into a chair with an individually adapted transfer according to the individual's resources.While sitting, functional tasks and activities of daily living will be performed and gradually increased to standing and walking exercises.
Study NCT05154786 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The weaning protocols, bed exercise, positioning, respiratory therapy, and early mobilization.
Study NCT05690802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron hydrochloride capsules
Description: This protocol only stipulates Palonosetron capsule containing hydrochloric acid protocol, and does not make uniform provisions on the treatment course, and does not interfere with the actual clinical usage and dosage.
Study NCT06347406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction combined with physiotherapy and education
Description: Blood flow restriction Physiotherapy exercises Education
Study NCT06347406 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blood flow restriction combined with physiotherapy and education
Description: Blood flow restriction Physiotherapy exercises Education
Study NCT05660239 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Community Intervention
Description: To evaluate the impact of a community intervention in reducing epilepsy stigma in adolescents.
Study NCT04923074 — intervention group
Intervention type: OTHER
Intervention: diffusion tensor imaging(DTI) evaluation
Description: DTI is a new kind of MRI technique to evaluate peripheral neuropathy
Study NCT06164067 — intervention group
Intervention type: OTHER
Intervention: abortus within 24 hours or 24-48 hours
Description: second trimester medical termination
Study NCT05682157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paula Method of muscle exercises
Description: 12 weekly sessions of Paula Method of exercise
Study NCT06199674 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: photobiomodulation therapy
Description: Patients in the PBM group will be delivered a portable PBM device (PBM Healing Ortho) at the beginning of orthodontic treatment and will be instructed to use it daily at home for 8 minutes (4 min per arch) after tooth brushing.
Study NCT06199674 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: orthodontic fixed-appliance
Description: All eligible patients will receive orthodontic treatment with a pre-adjusted fixed appliance (0.022'' × 0.028'' slot system, MBT, 3M Unitek) provided by the same practitioner. At the start of treatment, a cantilever auxiliary arch bent with a 0.017'' × 0.025'' Stainless Steel wire (3M Unitek) will be used to apply a 100 g intrusion force to the premolars that will be extracted in 3 months. All other teeth will undergo regular orthodontic treatment with a standard archwire protocol (0.014'' NiTi, 0.016'' NiTi, 0.018'' NiTi, 0.017'' × 0.025'' NiTi, 0.019'' × 0.025'' NiTi, and 0.019'' × 0.025'' SS, 0.019'' × 0.025'' TMA) for alignment, leveling, space closure, detailing, and finishing. For en masse retraction, a 150 g force will be applied by coil springs, allowing bracket slots to slide along the 0.019'' × 0.025'' SS.
Study NCT06199674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: orthodontic fixed-appliance
Description: All eligible patients will receive orthodontic treatment with a pre-adjusted fixed appliance (0.022'' × 0.028'' slot system, MBT, 3M Unitek) provided by the same practitioner. At the start of treatment, a cantilever auxiliary arch bent with a 0.017'' × 0.025'' Stainless Steel wire (3M Unitek) will be used to apply a 100 g intrusion force to the premolars that will be extracted in 3 months. All other teeth will undergo regular orthodontic treatment with a standard archwire protocol (0.014'' NiTi, 0.016'' NiTi, 0.018'' NiTi, 0.017'' × 0.025'' NiTi, 0.019'' × 0.025'' NiTi, and 0.019'' × 0.025'' SS, 0.019'' × 0.025'' TMA) for alignment, leveling, space closure, detailing, and finishing. For en masse retraction, a 150 g force will be applied by coil springs, allowing bracket slots to slide along the 0.019'' × 0.025'' SS.
Study NCT05692479 — intervention group
Intervention type: OTHER
Intervention: Premenstrual Syndrome Scale, Women's Physical Activity Self-Worth Inventory, Descriptive data
Description: Premenstrual Syndrome Scale, Women's Physical Activity Self-Worth Inventory, Descriptive data
Study NCT05729607 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vertical soft tissue augmentation
Description: Vertical soft tissue augmentation with autogenous connective tissue graft (CTG)
Study NCT05729607 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vertical soft tissue augmentation
Description: Vertical soft tissue augmentation with acellular dermal matrix (ADM) and enamel matrix derivative (EMD)
Study NCT05004051 — intervention group
Intervention type: DEVICE
Intervention: ViTAA Analysis
Description: Imaging Analysis Software
Study NCT05249829 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.529
Description: Sterile liquid for injection
Study NCT05249829 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1273
Description: Sterile liquid for injection
Study NCT05249829 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.214
Description: Sterile liquid for injection
Study NCT06414187 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-Aortic Balloon Pump
Description: Patients who are randomized to the IABP-arm will be supported with IABP according to local, clinical guidelines (including algorithms for anticoagulation, verification of correct positioning and weaning strategies). The IABP console and disposables should be used according to the instructions for use, including the use of an appropriate-sized IABP balloon alligned with patient length and height.
Study NCT05639660 — intervention group
Intervention type: OTHER
Intervention: non-interventional
Description: The treatment guideline recommends the 3+Q2m regimen for Aflibercept, but this study is an observational study, no intervention is made in the subjects' treatment regimen. There is no prescribed visit plan. According to the decision of the doctor and the patient according to the treatment plan, the patient needs to come to the clinic within the prescribed time window (3, 6, and 12 months) to facilitate the recording of data.
Study NCT05007808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G001 Topical Gel
Description: Non-steroidal anti-inflammatory drug for topical administration
Study NCT05007808 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Gel for topical administration
Study NCT06299085 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 50 adult patients suffering from severe or morbid obesity, male and female, candidates for bariatric surgery.
Description: 50 adult patients suffering from severe or morbid obesity (BMI ≥ 35 kg/m2 in the presence of comorbidities and BMI ≥ 40 kg/m2, respectively), male and female, candidates for bariatric surgery (Sleeve Gastrectomy and Roux-en-Y Gastric Bypass).~Two timepoints: T0 (pre-hospitalization) and T1 (follow-up 12 months +/- 1 month).~Expected assessments at T0 and T1:~* Blood chemistry tests to monitor metabolic markers involved in dietary and metabolic changes.~* Bone densitometry for body composition analysis (DEXA).~* Analysis of pre-intervention walking and the ability to recover motor activity after bariatric surgery using gait analysis.
Study NCT04822597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch
Description: Lidocaine is a local anesthetic.
Study NCT04822597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy(R)
Description: Buzzy provides non-invasive pain relief by vibrating and cooling the skin which distracts from pain sensations.
Study NCT04822597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice pack
Description: Ice cools the skin and can provide some numbing for pain.
Study NCT04822597 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ice pack
Description: Ice cools the skin and can provide some numbing for pain.
Study NCT05414487 — intervention group
Intervention type: DRUG
Intervention: Ofatumumab
Description: There is no treatment allocation. Patients with MS or NMOSD administered Ofatumumab by prescription will be enrolled. Participants will receive 20mg ofatumumab (20 mg/0.4 ml) by subcutaneous injection. Ofatumumab is administrated at baseline, Day 7, Day 14 and monthly thereafter until the end of the study.
Study NCT05880615 — intervention group
Intervention type: OTHER
Intervention: collection of datas
Description: collection of datas:~* Post-operative occurrence (within the first 48 hours after extubation) of post-operative delirium via the CAM-ICU (Confusion Assessment Method for the Intensive Care Unit) scale result~* Post-operative hypoxemia defined as a PaO2/FiO2 ratio \< 300 in the first 48 hours after extubation~* reflex ileus defined as the absence of gas and/or matter in the first 48 hours after extubation,~* total morphine consumption in the first 48 hours after surgery~* pain at 24 hours and 48 hours after surgery~* post-operative nausea and vomiting, major complications (neurological, respiratory, cardiac, infectious)~* mortality 30 days after surgery
Study NCT04647812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-assisted rehabilitation
Description: Augmented exercise therapy with novel technology and home-based telerehabilitation
Study NCT04647812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation
Description: Traditional multidisciplinary in-patient rehabilitation
Study NCT06004011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ARROW strategies
Description: ARROW strategies are peer-to-peer support at the patient, provider and health system levels
Study NCT06004011 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One-time education
Description: The comparison group will receive a one-time education campaign that will provide informational brochures to adolescents and young adults living with HIV and HIV providers
Study NCT05008861 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Capsulized Fecal Microbiota Transplant
Description: Capsules contained washed fecal microbiota.
Study NCT05008861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-programmed cell death protein 1/programmed death-ligand 1 monoclonal antibody
Description: Standard dose of one of anti-PD-1/PD-L1 mAbs administered as a 1 hour infusion every 3 weeks.
Study NCT05008861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum based chemotherapy
Description: Standard dose of Platinum based Chemotherapy every 3 weeks.
Study NCT05448781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostatin
Description: Eligible patients with advanced NSCLC were treated with endostatin combined with Tirelizumab and platinum-containing two-drug chemotherapy.26 cases of non-squamous cell carcinoma were treated with endostatin combined with Tirelizumab and Pemetrexed+Carboplatin. and 12 cases of squamous cell carcinoma were treated with endostatin combined with Tirelizumab and Paclitaxel/Albumin paclitaxel+Carboplatin,The maintenance treatment phase was continuous treatment with Endu combined with Tirelizumab
Study NCT05021094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kuntai Capsule
Description: The instructions is pointed that each Kuntai capsule is 0.5g and the usage of Kuntai capsule is oral taking 4 capsules each time, 3 times a day, and 4 weeks is a course of treatment. The patients will taking 3 courses of treatment in this study.
Study NCT05021094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Femoston
Description: The estrogen and progesterone sequential regimen was adopted. The Femoston was contain estradiol tablets and estradiol didroxyprogesterone tablets. Red tablets (estradiol, 2 mg/d) were taken in the first 14 days, and gray tablets (estradiol, 2 mg/d, dydrogesterone,10 mg/d) were taken in the last 14 days. 28 days was a course of treatment, and three courses of treatment were taken. The patients will taking 3 courses of treatment in this study.
Study NCT05021094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femoston
Description: The estrogen and progesterone sequential regimen was adopted. The Femoston was contain estradiol tablets and estradiol didroxyprogesterone tablets. Red tablets (estradiol, 2 mg/d) were taken in the first 14 days, and gray tablets (estradiol, 2 mg/d, dydrogesterone,10 mg/d) were taken in the last 14 days. 28 days was a course of treatment, and three courses of treatment were taken. The patients will taking 3 courses of treatment in this study.
Study NCT04824053 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk from genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium
Description: The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 250 mL of milk. The intervention duration will be 3 months
Study NCT04824053 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Conventional milk
Description: The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 250 mL of milk. The intervention duration will be 3 months
Study NCT04824053 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yogurt made from milk of genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium
Description: The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of one yogurt. The intervention duration will be 3 months